LG Chem Ltd. announced that it has completed its previously announced acquisition of AVEO Oncology. AVEO is also welcoming Martin Birkhofer, M.D. as its Chief Medical Officer. Dr. Birkhofer is an oncologist and seasoned business executive with more than 30 years of life sciences management experience.

Dr. Birkhofer joins AVEO with proven leadership abilities and extensive global clinical development, business development, regulatory and medical affairs experience with both small molecules and biologics. Dr. Birkhofer most recently served as Senior Vice President and Chief Medical Officer of Taiho Oncology Inc. Prior to joining Taiho Oncology, he served as Chief Medical Officer of Gradalis, Inc. and NuCana BioMed Ltd. Between 1994 and 2013, he served in various leadership roles within Research and Development and Business Development at Bristol-Myers Squibb (BMS). Dr. Birkhofer is Board Certified in Internal Medicine and Medical Oncology.

He obtained his M.D. from New York Medical College in Valhalla, New York.